Items where authors include "Hillmen, P"
Up a levelArticle
Hillmen, P, Pitchford, A, Bloor, A et al. (29 more authors) (2023) Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 24 (5). pp. 535-552. ISSN 1470-2045
Munir, T, Emmerson, J orcid.org/0000-0002-8198-8043, Hockaday, A et al. (9 more authors) (2022) Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial. British Journal of Haematology, 199 (5). pp. 707-719. ISSN 0007-1048
Richards, SJ, Dickinson, AJ, Newton, DJ orcid.org/0000-0002-0214-1486 et al. (1 more author) (2022) Immunophenotypic assessment of PNH clones in major and minor cell lineages in the peripheral blood of patients with paroxysmal nocturnal hemoglobinuria. Cytometry Part B - Clinical Cytometry, 102 (6). pp. 487-497. ISSN 1552-4949
Pike, A, McKinley, C, Forrest, B et al. (19 more authors) (2022) COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria. The Lancet Haematology, 9 (8). E553-E556. ISSN 2352-3026
Allsup, DJ, Craig, Z orcid.org/0000-0001-9930-6648, Cairns, D orcid.org/0000-0002-2338-0179 et al. (13 more authors) (2022) Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors. American Journal of Hematology, 97 (5). E168-E171. ISSN 0361-8609
Tam, CS, Robak, T, Ghia, P et al. (23 more authors) (2021) Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion. Haematologica, 106 (9). pp. 2354-2363. ISSN 0390-6078
Richards, SJ orcid.org/0000-0002-8421-5353, Painter, D, Dickinson, AJ et al. (14 more authors) (2021) The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK’s population‐based haematological malignancy research network 2004‐2018. European Journal of Haematology. ISSN 0902-4441
Allsup, D, Howard, D, Emmerson, J orcid.org/0000-0002-8198-8043 et al. (10 more authors) (2021) COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study. British Journal of Haematology. ISSN 0007-1048
Howard, DR, Hockaday, A, Brown, JM orcid.org/0000-0002-2719-7064 et al. (6 more authors) (2021) A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia. Trials, 22 (1). 38. ISSN 1745-6215
Eichhorst, B, Robak, T, Montserrat, E et al. (9 more authors) (2021) Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 32 (1). pp. 23-33. ISSN 0923-7534
Barrientos, JC, Hillmen, P orcid.org/0000-0001-5617-4403, Salles, G et al. (8 more authors) (2020) No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib. Leukemia & Lymphoma. ISSN 1042-8194
Pettitt, AR, Jackson, R, Cicconi, S et al. (23 more authors) (2020) Lenalidomide, Dexamethasone And Alemtuzumab Or Ofatumumab In High-Risk Chronic Lymphocytic Leukaemia: Final Results Of The NCRI CLL210 Trial. Haematologica, 105 (12). pp. 2868-2871. ISSN 0390-6078
Pike, A, Muus, P, Munir, T et al. (8 more authors) (2020) COVID‐19 infection in patients on anti‐complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience. British Journal of Haematology, 191 (1). E1-E4. ISSN 0007-1048
Tausch, E, Beck, P, Schlenk, RF et al. (18 more authors) (2020) Prognostic or predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. Haematologica: the hematology journal, 105 (10). pp. 2440-2447. ISSN 0390-6078
Offner, F, Robak, T, Janssens, A et al. (12 more authors) (2020) A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial. British Journal of Haematology, 190 (5). pp. 736-740. ISSN 0007-1048
Solman, IG, Blum, LK, Hoh, HY et al. (11 more authors) (2020) Ibrutinib Restores Immune Cell Numbers and Function in First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia. Leukemia Research. 106432. p. 106432. ISSN 0145-2126
Macrae, FL orcid.org/0000-0002-7092-0422, Peacock‐Young, B, Bowman, P et al. (12 more authors) (2020) Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab. American Journal of Hematology, 95 (8). pp. 944-952. ISSN 0361-8609
Richards, SJ orcid.org/0000-0002-8421-5353, Dickinson, AJ, Cullen, MJ et al. (8 more authors) (2020) Presentation clinical, haematological and immunophenotypic features of 1081 patients with GPI‐deficient (paroxysmal nocturnal haemoglobinuria) cells detected by flow cytometry. British Journal of Haematology, 189 (5). pp. 954-966. ISSN 0007-1048
Thomas, F, Holmes, KB, Kreuz, S et al. (2 more authors) (2020) DAPK3 participates in the mRNA processing of immediate early genes in Chronic Lymphocytic Leukaemia. Molecular Oncology, 14 (6). pp. 1268-1281. ISSN 1574-7891
Ghia, P, Coutre, SE, Cheson, BD et al. (7 more authors) (2020) Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase 3 randomized trial. Haematologica. ISSN 0390-6078
Davids, MS, Kuss, BJ, Hillmen, P orcid.org/0000-0001-5617-4403 et al. (13 more authors) (2020) Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. Clinical Cancer Research. ISSN 1078-0432
Brodsky, RA, Peffault de Latour, R, Rottinghaus, ST et al. (15 more authors) (2020) Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. ISSN 0390-6078
Munir, T, Brown, JR, O'Brien, S et al. (17 more authors) (2019) Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. American Journal of Hematology, 94 (12). pp. 1353-1363. ISSN 0361-8609
Fox, TA, Horne, GA, Craddock, C et al. (6 more authors) (2019) Trial re-investment to build better research for better impact. The Lancet, 394 (10199). pp. 635-636. ISSN 0140-6736
Norris, K, Hillmen, P orcid.org/0000-0001-5617-4403, Rawstron, A orcid.org/0000-0003-0798-9790 et al. (4 more authors) (2019) Telomere length predicts for outcome to FCR chemotherapy in CLL. Leukemia, 33 (8). pp. 1953-1963. ISSN 0887-6924
Appleby, N, Eyre, TA, Cabes, M et al. (7 more authors) (2019) The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease. BMC Cancer, 19 (1). 471. ISSN 1471-2407
Holmes, KB, Sadreev, II, Rawstron, AC orcid.org/0000-0003-0798-9790 et al. (4 more authors) (2019) Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells. Oncogenesis, 8. 32. ISSN 2157-9024
O'Brien, SM, Byrd, JC, Hillmen, P orcid.org/0000-0001-5617-4403 et al. (15 more authors) (2019) Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. American Journal of Hematology, 94 (5). pp. 554-562. ISSN 0361-8609
Socie, G, Caby-Tosi, M-P, Marantz, JL et al. (7 more authors) (2019) Eculizumab in paraxysmal nocturnal haemogloburinia and atypical haemolytic syndrome 10-year pharmacovigilance analysis. British Journal of Haematology, 185 (2). pp. 297-310. ISSN 0007-1048
Barrientos, JC, Burger, JA, Byrd, JC et al. (5 more authors) (2019) Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leukemia & Lymphoma, 60 (4). pp. 1000-1005. ISSN 1042-8194
Griffin, M, Hillmen, P orcid.org/0000-0001-5617-4403, Munir, T et al. (4 more authors) (2019) Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. Haematologica, 104 (3). e94-e96. ISSN 0390-6078
Kater, AP, Seymour, JF, Hillmen, P orcid.org/0000-0001-5617-4403 et al. (12 more authors) (2019) Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. Journal of Clinical Oncology, 34 (4). pp. 269-277. ISSN 0732-183X
Flinn, IW, Hillmen, P orcid.org/0000-0001-5617-4403, Montillo, M et al. (22 more authors) (2018) The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood, 132 (23). pp. 2446-2455. ISSN 0006-4971
Barrientos, JC, O'Brien, S, Brown, JR et al. (25 more authors) (2018) Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma Myeloma and Leukemia, 18 (12). 803-813.e7. ISSN 2152-2650
Robak, T, Burger, JA, Tedeschi, A et al. (23 more authors) (2018) Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies. American Journal of Hematology, 93 (11). pp. 1402-1410. ISSN 0361-8609
Varghese, AM, Rawstron, A orcid.org/0000-0003-0798-9790, Newton, D orcid.org/0000-0002-0214-1486 et al. (5 more authors) (2018) Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia. British Journal of Haematology, 182 (6). pp. 927-930. ISSN 0007-1048
Alharthi, A, Beck, D, Howard, DR orcid.org/0000-0003-3333-9783 et al. (4 more authors) (2018) An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects. BMC Research Notes, 11 (1). 280. ISSN 1756-0500
Seymour, JF, Kipps, TJ, Eichhorst, B et al. (17 more authors) (2018) Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine, 378 (12). pp. 1107-1120. ISSN 0028-4793
Rawstron, AC orcid.org/0000-0003-0798-9790, Kreuzer, K-A, Soosapilla, A et al. (30 more authors) (2018) Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry Part B: Clinical Cytometry, 94 (1). pp. 121-128. ISSN 1552-4949
Brown, JR, Hillmen, P orcid.org/0000-0001-5617-4403, O'Brien, S et al. (27 more authors) (2018) Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE(TM) study in patients with previously treated CLL/SLL. Leukemia, 32. pp. 83-91. ISSN 0887-6924
Brown, JR, Moslehi, J, O' Brien, S et al. (24 more authors) (2017) Characterization Of Atrial Fibrillation Adverse Events Reported In Ibrutinib Randomized Controlled Registration Trials. Haematologica, 102 (10). pp. 1796-1805. ISSN 0390-6078
Munir, T, Howard, DR orcid.org/0000-0003-3333-9783, McParland, L et al. (12 more authors) (2017) Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. Leukemia, 31 (10). pp. 2085-2093. ISSN 0887-6924
Collett, L, Howard, DR orcid.org/0000-0003-3333-9783, Munir, T et al. (11 more authors) (2017) Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials, 18. 387. ISSN 1745-6215
Oughton, JB orcid.org/0000-0002-2047-804X, Collett, L, Howard, DR orcid.org/0000-0003-3333-9783 et al. (8 more authors) (2017) GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial. Trials, 18. 353. ISSN 1745-6215
Agathanggelou, A, Smith, E, Davies, NJ et al. (20 more authors) (2017) USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status. Blood, 130 (2). pp. 156-166. ISSN 0006-4971
Barr, PM, Brown, JR, Hillmen, P orcid.org/0000-0001-5617-4403 et al. (19 more authors) (2017) Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood, 129 (19). pp. 2612-2615. ISSN 0006-4971
Howard, DR orcid.org/0000-0003-3333-9783, Munir, T, McParland, L et al. (12 more authors) (2017) Results of the randomized phase IIB ARCTIC trial of low dose Rituximab in previously untreated CLL. Leukemia, 31. pp. 2416-2425. ISSN 0887-6924
Varghese, A, Howard, DR orcid.org/0000-0003-3333-9783, Pocock, C et al. (9 more authors) (2017) Eradication of minimal residual disease improves overall and progression free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: A Phase II trial assessing alemtuzumab consolidation. British Journal of Haematology, 176 (4). pp. 573-582. ISSN 0007-1048
Ryan, CE, Sahaf, B, Logan, AC et al. (13 more authors) (2016) Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood, 128 (25). pp. 2899-2908. ISSN 0006-4971
Kwok, M, Rawstron, AC, Varghese, A et al. (6 more authors) (2016) Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood, 128 (24). pp. 2770-2773. ISSN 0006-4971
Worrillow, L, Baskaran, P, Care, MA et al. (9 more authors) (2016) An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukemia cases using multiple polymerases. Oncogene, 35 (40). pp. 5328-5336. ISSN 0950-9232
Howard, DR orcid.org/0000-0003-3333-9783, Munir, T, Hockaday, AM et al. (7 more authors) (2016) Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial. Trials, 17. 456. ISSN 1745-6215
Buehler, A, Wendtner, C-M, Kipps, TJ et al. (17 more authors) (2016) Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer Journal, 6. ARTN e404. ISSN 2044-5385
Kwok, M, Davies, N, Agathanggelou, A et al. (12 more authors) (2016) ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood, 127 (5). pp. 582-595. ISSN 0006-4971
Burger, JA, Tedeschi, A, Barr, PM et al. (31 more authors) (2015) Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. New England Journal of Medicine, 373 (25). pp. 2425-2437. ISSN 0028-4793
Parrish, C, Scott, GB, Migneco, G et al. (13 more authors) (2015) Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia. Leukemia, 29 (9). 1799 - 1810. ISSN 0887-6924
El-Sherbiny, YM, Doody, GM, Kelly, RJ et al. (3 more authors) (2015) Natural killer (NK) cell function in paroxysmal nocturnal hemoglobinuria: A deficiency of NK cells, but not an NK cell deficiency. Blood, 125 (8). 1351 - 1352. ISSN 0006-4971
El-Sherbiny, YM, Kelly, RJ, Hill, A et al. (3 more authors) (2013) Altered natural killer cell subset homeostasis and defective chemotactic responses in paroxysmal nocturnal hemoglobinuria. Blood, 122 (11). 1887 - 1890. ISSN 0006-4971
Hillmen, P orcid.org/0000-0001-5617-4403, Muus, P, Röth, A et al. (11 more authors) (2013) Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology, 162 (1). pp. 62-73. ISSN 0007-1048
Monograph
Howard, DR orcid.org/0000-0003-3333-9783, Munir, T, McParland, L et al. (9 more authors) (2017) Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial. Report. National Institute for Health Research , Health Technology Assessment. ISSN 1366-5278
Conference or Workshop Item
Roeth, A, Hillmen, P orcid.org/0000-0001-5617-4403, Szer, J et al. (16 more authors) (2020) Results of the PEGASUS phase 3 randomized trial demonstrating superiority of the C3 inhibitor, pegcetacoplan, compared to eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH). In: Conference of the German, Austrian and Swiss Societies for Hematology and Medical Oncology, 09-11 Oct 2020, Online.
Newton, DJ, McKinley, CE, Ricardo, A et al. (8 more authors) (2017) Assessment of Eculizumab and C5 Levels in PNH Treatment: Molar Ratio of Eculizumab to C5 Level Effectively Predicts Ongoing Dosage Changes in a Cohort of 50 Patients Treated with Eculizumab. In: 59th ASH Annual Meeting Abstracts, 09-12 Dec 2017, Atlanta, GA, USA.
McKinley, CE orcid.org/0000-0003-4006-8846, Richards, SJ, Munir, T et al. (8 more authors) (2017) Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome. In: 59th ASH Annual Meeting, 09-12 Dec 2017, Atlanta, GA, USA.
Farag, SMK, Newton, D, Doody, G et al. (4 more authors) (2016) Molecular Mechanisms of Ibrutinib Resistance: Defining a Logical Approach to Improving Targeted Therapy in CLL. In: 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA.
Rawstron, A, Cohen, D, de Tute, R et al. (8 more authors) (2015) BONE MARROW IS MORE SENSITIVE THAN PERIPHERAL BLOOD FOR DETECTION OF MRD IN CLL AND PROVIDES A MORE RELIABLE PREDICTION OF OUTCOME ACROSS DIFFERENT TREATMENTS. In: European Haematology Association Congress, 11-14 Jun 2015, Vienna, Austria.
Proceedings Paper
Peffault De Latour, R, Mitchell, L, Brodsky, RA et al. (10 more authors) (2019) Ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: pharmacokinetics and pharmacodynamics observed in two Phase 3 randomized, multicenter studies. In: British Journal of Haematology. 59th Annual Scientific Meeting of the British Society for Hematology, 01-03 Apr 2019, Glasgow, UK. Wiley , p. 110.
Munir, T, Howard, D orcid.org/0000-0003-3333-9783, McParland, L et al. (10 more authors) (2018) Obinutuzumab as consolidation after chemo-immunotherapy is highly effective in achieving MRD clearance from bone marrow and peripheral blood-Initial results of UK NCRI Phase II/III GALACTIC trial. In: British Journal of Haematology. 58th Annual Scientific Meeting of the British Society for Haematology, 16-18 Apr 2018, Liverpool, UK. Wiley , p. 79.
Macrae, F, Bowman, P, Linton, E et al. (13 more authors) (2017) Fibrinogen and Clot Structure Is Affected By Eculizumab in Patients with Paroxysmal Nocturnal Haemoglobinuria. In: Blood. 59th Annual Meeting of the American-Society-of-Hematology, 09-12 Dec 2017, Atlanta, GA. American Society of Hematology , p. 462.
Holmes, K, Lefevre, P, Sadreev, I et al. (4 more authors) (2017) Ibrutinib mediates changes in chromatin structure in chronic lymphocytic leukaemia (CLL): epigenetic studies from the bloodwise TAP IcICLLe trial. In: Leukemia and Lymphoma. XVII International Workshop on Chronic Lymphocytic Leukemia, 12-15 May 2017, New York, USA. Taylor and Francis , pp. 19-20.
Burger, J, Tedeschi, A, Barr, PM et al. (32 more authors) (2016) International, randomized phase 3 study results: Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM)). In: Oncology Research and Treatment. Annual conference of the German, Austrian and Swiss Societies for Haematology and Medical Oncology, 14-18 Oct 2016, Leipzig, Germany. Karger Publishers , p. 6.